Bullish & Foolish
Full BMEA fundamentals All 466 on the Survival Watch

BMEABiomea Fusion, Inc.

Is Biomea Fusion struggling financially?

Yes, by its own account. Biomea Fusion told the SEC on 11 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Cries for help

  • Needs to raise money

    We will need to raise additional capital in the future to fund our operations, including to conduct and complete clinical trials for any product candidates.

    Form 10-Q, filed 11 May 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$99.3M
Source filing
10-Q 11 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 3months

    If the burn speeds up

    Empty by Sep 2026

  • 5months

    If it eases off

    Empty by Nov 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$34.8M

÷

Cash burned over the last 12 months

$103.7M

What Biomea Fusion told the SEC

…financing will be available to the Company or that such financing, if available, will be available on terms acceptable to the Company. Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern. The Company has historically financed its operations primarily through the sale of common stock and warrants and the issuance of unsecured promissory notes. To date, none of the…

Biomea Fusion, Inc., Form 10-Q, filed 11 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 87.2% share-count increase The company issued stock. Each share now owns 46.6% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 46% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt